All In MedTech

Device Trial Radar · NCT07866768

CMN LIFU for Enhanced Amyloid Reduction (CLEAR Study)

Safety and Feasibility Study of ATTN201 Centromedian Nucleus of the Thalamus Focused Ultrasound Stimulation for Enhanced Glymphatic Clearance in Amyloid Positive Patients With Mild Cognitive Impairment

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Attune Neurosciences Inc; Gates Ventures
First posted
Oct 8, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if a wearable ultrasound device, called ATTN201, is safe and easy to use. The study is for adults ages 65 and older who have mild cognitive impairment (MCI) and a buildup of a protein called amyloid in the brain. Amyloid buildup is an early sign of Alzheimer's disease. The ATTN201 device sends low-intensity sound waves to a deep area of the brain that helps control sleep. The aim is to boost deep-sleep brain waves. These brain waves may help the brain clear away waste, including amyloid. The main questions it aims to answer are: 1. What, if any, issues do participants have when using the ATTN201 device? 2. Can participants complete the full study schedule? Researchers will compare focused ultrasound to unfocused ultrasound. Unfocused ultrasound is a look-alike treatment. It feels and sounds the same but is not aimed at the brain target. The comparison will show if the focused treatment changes sleep brain waves, blood markers of Alzheimer's disease, or memory and thinking. Participants will: * Visit the study site for memory and thinking tests, blood draws, a health check, and MRI scans of the brain * Record their sleep at home for at least 5 days with a sleep diary, a watch-like sensor, and a headband that measures brain waves * Be assigned by chance to focused or unfocused ultrasound * Take part in 10 nap sessions over 2 weeks while wearing the device, at the study site or at home * Return for a final visit to repeat the first tests, and may return for an optional visit 3 months later

Conditions

  • Alzheimer's Disease (AD)
  • Mild Cognitive Impairment (MCI)
  • Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease

Interventions

  • ATTN201 Focused Ultrasound to the CMNDevice

    Low-intensity focused ultrasound delivered to the centromedian nucleus of the thalamus by the investigational ATTN201 head-worn device.

  • ATTN201 Unfocused UltrasoundDevice

    Unfocused ultrasound delivered by the same device, serving as the control condition.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, Severity, and Relatedness of Adverse Events and Serious Adverse EventsTime frame: From informed consent through the 3-month follow-up visit (up to ~5 months)
  2. Incidence of New Clinically Significant Findings on Post-Treatment Safety MRITime frame: From baseline through the post-treatment (~Week 5)
  3. Study completion rate and adherence to scheduled study proceduresTime frame: From baseline through the post-treatment (~Week 5)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.